Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Aurobindo Pharma secures USFDA final approval for multi-strength Perampanel tablets

4 October 2026 · By · Wire by Fusion42

Published

4 October 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at indianpharmapost.com →

◆ Verified

Fusion42 · 5 October 2026 · Fusion42 review

Aurobindo Pharma has received final USFDA approval to manufacture and market generic Perampanel Tablets in six dosage strengths with a market size of $67 million. The product will be manufactured at APL Healthcare's Unit-IV and launched in Q3FY27.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

The US market for Perampanel tablets is now open to you as a generic drug maker with Aurobindo Pharma's approval. You can plan to compete in a $67 million segment starting next year, cutting into branded drug dominance.

◆ Coverage

1 source · 4 Oct 2026

◆ Related on Wire

◆ Topics

Biotechusfdadrug-approvalgeneric-drugspharmaperampanel